Drug Profile
CX 480
Latest Information Update: 04 Nov 1996
Price :
$50
*
At a glance
- Originator Cortex Pharmaceuticals
- Class Antidementias; Neuroprotectants
- Mechanism of Action Neurotransmitter stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 04 Nov 1996 Discontinued-Preclinical for Alzheimer's disease in USA (Unknown route)
- 18 Apr 1996 New profile
- 18 Apr 1996 Preclinical development for Alzheimer's disease in USA (Unknown route)